Physician profile
Michael L Hubner
NPI 1245265834
$2,059.09
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,011 · 2020: $271 · 2021: $184 · 2022: $410 · 2023: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $183.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $292.71 | 2019-2023 | Veozah |
| Amgen INC. | $287.74 | 2019-2023 | Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $181.43 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $179.43 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $144.46 | 2019-2023 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $142.06 | 2019-2020 | |
| Novo Nordisk INC | $136.38 | 2019-2023 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.06 | 2019-2022 | |
| Lilly USA, LLC | $110.62 | 2019-2022 | |
| Glaxosmithkline, LLC. | $82.21 | 2019-2023 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $58.03 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $56.42 | 2019 | |
| Boston Scientific Corporation | $54.12 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.97 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $26.69 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nabriva Therapeutics, Plc | $21.46 | 2022 | |
| Sobi, INC | $21.03 | 2023 | |
| Acadia Pharmaceuticals INC | $17.91 | 2020 | |
| Amarin Pharma, INC. | $15.39 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.34 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.87 | 2019 | |
| Esperion Therapeutics, INC. | $13.19 | 2022 | |
| Arbor Pharmaceuticals, INC. | $11.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hubner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.